ScreenerHero

ETON Eton Pharmaceuticals, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · etonpharma.com
54.77USD-1.53%Mkt Cap: 1.57B $P/E: 136.93

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.69BUSDP/E 25.5
TAK
Takeda Pharmaceutical Company Limited
$57.82BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.64BUSDP/E 65.2
HLN
Haleon plc
$39.01BUSDP/E 18.1
ZTS
Zoetis Inc.
$29.48BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.23BUSDP/E 19.4
VTRS
Viatris Inc.
$20.15BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.27BUSDP/E 111.6
NBIX
Neurocrine Biosciences, Inc.
$14.79BUSDP/E 21.3
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.23BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.40BUSDP/E 28.4
KRK
Krka, d. d.
$8.63BUSDP/E 19.3
AMRX
Amneal Pharmaceuticals, Inc.
$7.07BUSDP/E 41.4
ALKS
Alkermes plc
$6.99BUSDP/E 109.6
HIMS
Hims & Hers Health, Inc.
$6.88BUSD
LNTH
Lantheus Holdings, Inc.
$6.53BUSDP/E 24.2
KNSA
Kiniksa Pharmaceuticals International, plc
$5.93BUSDP/E 77.9
APTX
Apotex Health Corp.
$5.27BUSD

Key Statistics

Company
Market Cap1.57B USD
Enterprise Value1.58B USD
Revenue (TTM)105.59M USD
Gross Profit42.74M USD
Net Income (TTM)-4.60M USD
Revenue/Share3.88 USD
Last Price54.77 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees44
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)136.93
P/E (Forward)21.46
PEG—
EV/EBITDA62.94
EV/Revenue15.01
P/S14.99
P/B33.61
EPS (TTM)0.40
EPS (Forward)2.58
52W Range
14.2778% of range66.37
52W High66.37 USD
52W Low14.27 USD
Profitability
Gross Margin53.46%
Oper. Margin35.77%
EBITDA Margin23.84%
Profit Margin-5.75%
ROE-17.59%
ROA-4.99%
Growth
Revenue Growth98.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF10.52M USD
CapEx (TTM)333.00K USD
FCF Margin6.23%
FCF Yield0.42%
Net Debt2.38M USD
Net Debt/EBITDA0.09
Balance Sheet
Debt/Equity1.19
Current Ratio1.52
Quick Ratio1.15
Book Value/Sh1.65 USD
Cash/Share0.94 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)71.00 USD
Upside (mean)+29.6%
Target Range68.00 USD – 76.00 USD
68.00+29.6% to mean76.00
# Analysts4
Ownership
Shares Out.28.58M
Float22.30M
Insiders4.87%
Institutions71.00%
Short Interest
Short Ratio2.7d
Short % Float7.46%
Short % Out.5.40%
Shares Short1.54M
Short (prev mo.)1.43M
Technical
SMA 5054.61 (+0.3%)
SMA 20032.11 (+70.6%)
Beta0.90
S&P 52W Chg14.58%
Avg Vol (30d)656.94K
Avg Vol (10d)740.62K
Technical Indicators
RSI (14)49.0
MACD0.3812
MACD Signal1.1342
MACD Hist.-0.7531
BB Upper61.25 USD
BB Middle56.62 USD
BB Lower51.99 USD
BB Width16.36%
ATR (14)3.533 USD
Vol Ratio (20d)0.80x